HighPoint Advisor Group LLC Invests $185,000 in Autolus Therapeutics plc (NASDAQ:AUTL)

HighPoint Advisor Group LLC purchased a new stake in Autolus Therapeutics plc (NASDAQ:AUTL) during the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 78,620 shares of the company’s stock, valued at approximately $185,000.

Other hedge funds have also bought and sold shares of the company. Wellington Management Group LLP grew its position in Autolus Therapeutics by 4.6% during the fourth quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company’s stock worth $59,562,000 after buying an additional 1,125,454 shares in the last quarter. BIT Capital GmbH grew its holdings in shares of Autolus Therapeutics by 147.0% during the 4th quarter. BIT Capital GmbH now owns 636,979 shares of the company’s stock worth $1,497,000 after purchasing an additional 379,050 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Autolus Therapeutics by 21.2% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 82,411 shares of the company’s stock worth $194,000 after purchasing an additional 14,432 shares during the period. EntryPoint Capital LLC acquired a new stake in Autolus Therapeutics during the fourth quarter worth about $450,000. Finally, Privium Fund Management B.V. increased its holdings in Autolus Therapeutics by 24.8% in the 4th quarter. Privium Fund Management B.V. now owns 231,674 shares of the company’s stock valued at $544,000 after buying an additional 46,035 shares during the period. 72.83% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on AUTL shares. Truist Financial cut their price target on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday. Wells Fargo & Company decreased their price target on Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating on the stock in a research note on Friday, March 21st. Finally, Needham & Company LLC restated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Monday, January 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $9.32.

Autolus Therapeutics Stock Performance

Shares of NASDAQ:AUTL opened at $1.33 on Friday. Autolus Therapeutics plc has a 52-week low of $1.31 and a 52-week high of $5.70. The company has a market capitalization of $353.91 million, a PE ratio of -1.10 and a beta of 2.06. The company has a fifty day moving average of $1.88 and a 200-day moving average of $2.74.

Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12. The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $2.98 million. On average, equities analysts forecast that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.